The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary
disease (COPD) vary in their pharmacological class (β 2-adrenergic agonist or …

Educational aims To discuss fundamental questions relating to the use of bronchodilators
that can lead to an optimisation of their utilisation. To describe new bronchodilators that …

Current evidence supports the recommendation of the Global Initiative for Chronic
Obstructive Lung Disease guidelines of at least one of the two classes of long-acting inhaled …

Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Bronchodilators are the cornerstone of symptomatic treatment for all chronic obstructive
pulmonary disease (COPD) severity stages when administered on a regular basis to prevent …

Introduction This post hoc analysis of the “Early MAXimization of bronchodilation for
improving COPD stability”(EMAX) trial investigated whether patients achieving early …

Objective: To review clinical data on the use of long-acting bronchodilator agents as
monotherapy and in combination for the treatment of moderate-to-severe chronic obstructive …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICSs) …

Chronic obstructive pulmonary disease (COPD) is a treatable disease characterized by
progressive airflow limitation. Prevention of disease progression, improvement of symptoms …

Bronchodilators are the mainstay of chronic obstructive pulmonary disease (COPD) therapy.
Inhaled short-acting β2-agonists generally have a more rapid onset of effect and shorter …